Bone Biologics Co. (NASDAQ:BBLG – Get Free Report) saw a large increase in short interest in the month of January. As of ...

According to the company, in order to be enrolled in the study, patients must have DDD at one level from L2-S1 and may also ... There are approximately 350,000 spinal fusion surgeries done in ...

Elevated preoperative beta-human chorionic gonadotropin levels were noted ... An intramedullary tumour measuring 5 × 1.5 cm was identified within the T12–L2 region on her first lumbar spine MRI dated ...

Fourteen months after starting first-line therapy: Evidence of progressive disease (PD), with new areas of bone involvement in T-spine, left ribs, and L2 Circulating tumor ... in hormone ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

An allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...

“Human spinal circuitry is very sophisticated – it’s not just a bunch of reflexes controlled by the brain,” said Harkema, now with the Kessler Foundation a rehabilitation research nonprofit.